RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
181 hedge funds and large institutions have $2.69B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 71 increasing their positions, 55 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less first-time investments, than exits
New positions opened: | Existing positions closed:
58% less call options, than puts
Call options by funds: $39.3M | Put options by funds: $94.7M
71% less funds holding in top 10
Funds holding in top 10: 7 → 2 (-5)
Holders
181
Holding in Top 10
2
Calls
$39.3M
Puts
$94.7M
Top Buyers
| 1 | +$63.3M | |
| 2 | +$22.1M | |
| 3 | +$11.6M | |
| 4 |
Morgan Stanley
New York
|
+$9.65M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$7.84M |
Top Sellers
| 1 | -$42.5M | |
| 2 | -$36.6M | |
| 3 | -$11.1M | |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$10.1M |
| 5 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$10.1M |